Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma

NCT06574126 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

High Risk Smoldering Multiple Myeloma

Interventions

DRUG: Group 1: Dara-VRD followed by apheresis and cilta-cel infusion
DRUG: Group 2: Apheresis followed by Dara-VRD and cilta-cel infusion

Sponsor

PETHEMA Foundation